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valdecoxib), valdecoxib had a lower cost (€0.26) per
treatment day (95% CI: €-3.23, €2.72). The cost differ-
ence associated with GI-SAEs per treatment day was
lower for valdecoxib: €1.57 (95% CI; €3.90, €0.75).
CONCLUSIONS: Valdecoxib relative to diclofenac has
signiﬁcantly lower hospitalization costs per patient, and
the total costs for the two treatments are not signiﬁcantly
different, indicating that the superior safety beneﬁts with
valdecoxib might be achieved without an increase in total
treatment costs.
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OBJECTIVES: To evaluate the cost-effectiveness of etori-
coxib, a new selective Cox-2 inhibitor, in the treatment
of acute gouty arthritis compared with indomethacin in
the United Kingdom. METHODS: Using a recent clinical
trial comparing etoricoxib with indomethacin in the treat-
ment of acute gouty arthritis, a Markov model was built
based on four 8-day treatment cycles spread over four
years. In the trial, etoricoxib and indomethacin demon-
strated equivalent efﬁcacy but adverse event (AE) and
treatment discontinuation rates favored etoricoxib. In cal-
culating the total cost for each type of AE, its frequency
in the trial was taken into account. The medical treatment
of AEs and the average predicted probability of seeking
treatment were obtained from expert opinion and used
for the base case analysis. In the model, all patients suf-
fering an AE or discontinuing treatment selected a differ-
ent treatment for their next gout attack. The model
further assumed a general practitioner would treat all
patients and that an AE could necessitate one additional
GP visit. RESULTS: After one cycle of treatment the
incremental cost per patient successfully treated with
etoricoxib (no AE or discontinuation), including drug
therapy costs, was £15.43, decreasing to £6.27 over 4
cycles of treatment. CONCLUSION: In this study, etori-
coxib was a cost-effective alternative to indomethacin for
treatment of acute gouty arthritis based on the modelling
calculations using published clinical trial data and con-
servative assumptions regarding the treatment of AEs.
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OBJECTIVE: To determine the incremental cost-
effectiveness of COX-2-selective versus non-selective non-
steroidal anti-inﬂammatory drugs (NSAIDs) in relation 
to bleeding in a cohort of coumarin users. METHODS:
A pharmacoeconomic evaluation was linked to a case-
control design within an observational study in con-
comitant NSAID and coumarin users (with versus
without bleeding). Medical costs associated with bleeding
as well as costs associated with NSAID-use were deter-
mined, according to the Dutch guideline prices and
Health care tariffs. Rofecoxib, meloxicam, and nabume-
tone were considered to be COX-2-selective. Total costs
were calculated and compared for two hypothetical sce-
narios in which patients would use either COX-2-
selective NSAIDs or non-selective NSAIDs. Sensitivity
analyses were performed varying both the Odds Ratio
(OR) and costs of NSAIDs and bleedings. RESULTS:
A total of 1491 bleeding complications were detected
among 4400 coumarin users. Of the bleeders, 14.8% 
(n = 221) used a non-selective (96.1%) or COX-2-
selective (3.9%) NSAID. The OR for bleeding was 3.07
(95% CI 1.18–8.03) for non-selective versus COX-2-
selective NSAIDs. The mean cost of a bleeding was €478.
Factoring in the excess costs of COX-2-selective over
non-selective NSAID-use resulted in net savings of
€53,786. In the sensitivity analysis, cost savings remained,
except for situations with the OR in the lower range of
the conﬁdence interval (1.18–1.26). CONCLUSIONS: In
coumarin users, the reduction of bleeding complications
by the more expensive COX-2-selective inhibitors (com-
pared with non-selective NSAIDs) is also associated with
medical cost savings.
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OBJECTIVES: To assess the average prescribed daily
dose and cost of the two reimbursed coxibs, rofecoxib
and celecoxib, in Norway. Given the drugs’ different price
structures, prescribed number of tablets and strength
impact the daily treatment cost differentially. As a pre-
requisite for continued general reimbursement for rofe-
coxib and celecoxib from July 1, 2003, the Norwegian
Ministry of Health required post-marketing data regard-
ing prescription patterns in clinical practice to further
evaluate the drugs’ relative cost effectiveness. The Min-
istry’s re-evaluation will be based on this and other
studies. METHODS: All accessible physicians within the
ﬁeld of rheumatology (specialists) in Norway were invited
to prospectively register their prescriptions of reimbursed
coxibs for patients with Rheumatoid Arthritis (RA)
and/or Osteoarthritis (OA), over a period of 2 months
(October to December 2002). Data from registration
forms and patient records were collected through per-
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sonal interviews with physicians. RESULTS: Prescriptions
for 276 patients (66% women), average age 56 years
(18–88), were collected from 20 specialists. A total of 249
patients had RA (90%), 15 OA (5%) and 12 both (4%).
Fifty-three percent were celecoxib prescriptions, 47%
rofecoxib. Eighty-four percent of 117 rofecoxib prescrip-
tions to RA patients were of 25mg strength. Of these,
95% were dosed 1 ¥ 1 and the average daily number of
tablets was 1.05. Ninety-four percent of 132 celecoxib
prescriptions to RA patients were of 200mg strength. 
Of these, 68% were dosed 1 ¥ 2, and the average daily
number of tablets was 1.86. The average weighted cost
per day for celecoxib was NOK 16.75, and 11.78 for
rofecoxib (pharmacy selling prices). CONCLUSION:
This study by itself does not allow for an assessment of
the drugs’ relative cost-effectiveness. However, the pre-
scription pattern observed among specialists for reim-
bursed cox-2 inhibitors for RA patients indicates a higher
daily drug cost for celecoxib than for rofecoxib.
PAR9
PATTERNS OF USE, DOSING AND ECONOMIC
IMPACT OF BIOLOGIC AGENTS IN PATIENTS
WITH RHEUMATOID ARTHRITIS
Gilbert TD, Smith D, Pedan A, Ollendorf D
PharMetrics Inc, Watertown, MA, USA
OBJECTIVE: Variability in dosing of biologic agents
among patients with rheumatoid arthritis (RA), and asso-
ciated economic impact, is of great interest to payers and
providers. We examined dosing patterns for patients with
RA who were newly treated with inﬂiximab or etanercept
as well as corresponding 1-year costs of care.
METHODS: Integrated pharmacy and medical claims
data were obtained from 61 U.S. health plans. Patients
with a diagnosis of RA who were newly treated with
inﬂiximab or etanercept from July 1999 to June 2002
were selected. Among inﬂiximab patients, a maintenance
number of vials was determined after the “loading
period” (2–3 infusions); those with ≥2 occurrences of an
increase in vials or an interval between infusions of <49
days were considered to have had escalated. For etaner-
cept patients, a maintenance dose was measured on the
second prescription based on the average daily dose dis-
pensed (in mg); those with ≥2 instances of increased
average doses were considered to have escalated their
dose. RA-related costs at one year post-initiation were
examined; statistical comparisons were made using gen-
eralized linear models with a gamma distribution.
RESULTS: A total of 1548 patients were identiﬁed (n =
598 and 950 for inﬂiximab and etanercept respectively).
Inﬂiximab recipients were somewhat older (50.5 vs. 46.6
years for etanercept). Nearly 60% of inﬂiximab patients
experienced an increase in dose at one year, compared to
18% of patients new to etanercept. Inﬂiximab patients
who experienced a dose increase had signiﬁcantly higher
annual RA-related costs than those with no increase
($20,915 vs. $16,713; p < 0.0001). Costs among etaner-
cept patients did not substantially differ based on dose
escalation ($14,482 vs. $13,866 respectively). CON-
CLUSIONS: Patients new to inﬂiximab had much higher
rates of dose escalation relative to etanercept recipients.
These dose increases resulted in signiﬁcantly higher
medical costs at one year.
ARTHRITIS—Quality of Life Studies
PAR10
CROSS-CULTURAL ADAPTATION AND
VALIDATION OF KOREAN VERSION OF EQ-5D
IN PATIENTS WITH RHEUMATIC DISEASES
Bae SC1, Kim MH2
1Hanyang University, Seoul, Korea, Seoul, South Korea; 2Eulji
University School of Medicine, Daejon, South Korea
OBJECTIVE: This study aims at translating and adapt-
ing the EQ-5D cross-culturally into Korean (KEQ-5D),
and evaluating its reliability and validity among patients
with various rheumatic diseases. METHODS: The EQ-
5D was translated into Korean by 2 translators and back
into English by another 2 translators. Then lay assessment
was done according to the EuroQol Group’s translation
guidelines. Based on the repeated measure data of 65
patients with rheumatoid arthritis (RA), we examined
test-retest reliability by intra-class correlation (ICC), and
responsiveness by effect size and t-statistic. To evaluate
validity, we recruited 100 patients with RA, 103 with
osteoarthritis (OA), 111 with systemic lupus erythemtous
(SLE), 104 with ﬁbromyalgia syndrome (FMS), and 90
with ankylosing spondylitis (AS). For concurrent validity,
we explored correlation between the KEQ-5D and KEQ-
VAS (visual analog scale), KSF-36 global, utility measures
such as time-trade off (TTO) and standard gamble
(SGM), and disease-speciﬁc measures, including KHAQ
and for RA, KWOMAC for OA, SLEDAI and SLICC for
SLE, KFIQ for FMS, and KBASFI for AS. RESULTS: Test-
retest reliability measured by ICC was 0.635. The effect
size was 0.683. Correlations with KEQ-VAS and SF-36
global were signiﬁcant, however those with TTO and
SGM were not. Correlations with disease-speciﬁc mea-
sures were all signiﬁcant except for SLEAI and SLICC 
in SLE, ranging from -0.477 to -0.603. Correlations
between physical domains of KEQ-5D and KSF-36P were
higher those with KSF-36M, on the contrary, correlation
between anxiety/depression and KSF-36M was higher
than that with KSF-36P in both overall and disease-
speciﬁc analysis. CONCLUSION: These ﬁndings indi-
cated that KEQ-5D had stability and responsiveness, and
moreover, criterion and construct validity were satisfac-
tory. We concluded that KEQ-5D could be applied to
Korean patients with various rheumatic diseases.
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